Viking Debt To Equity from 2010 to 2024

VKTX Stock  USD 54.51  1.09  2.04%   
Viking Therapeutics Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.00092991
Current Value
0.000976
Quarterly Volatility
0.36652685
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 277.4 K, Interest Expense of 83.6 K or Selling General Administrative of 38.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.29. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viking Therapeutics Correlation against competitors.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Latest Viking Therapeutics' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Viking Therapeutics over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Viking Therapeutics' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.01 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Viking Debt To Equity Regression Statistics

Arithmetic Mean(0.1)
Coefficient Of Variation(370.79)
Mean Deviation0.26
Median0.001
Standard Deviation0.37
Sample Variance0.13
Range1.5188
R-Value0.48
Mean Square Error0.11
R-Squared0.23
Significance0.07
Slope0.04
Total Sum of Squares1.88

Viking Debt To Equity History

2024 9.76E-4
2023 9.3E-4
2022 0.002092
2021 1.44E-4
2020 0.001351
2018 0.00109
2017 0.26

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.